NEW YORK and HOLLISTON, Mass., Feb. 1, 2016 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced that CEO Jim McGorry will present at the Source Capital Disruptive Growth & Healthcare Conference in New York City on Wednesday, February 10, 2016 at 3:30 pm EST. HART's presentation will be webcast live and available for replay.
Live Webcast/Replay: http://wsw.com/webcast/sourcecap1/hart
About HART: (www.hartregen.com)
Harvard Apparatus Regenerative Technology (HART) makes bioengineered implants for life-threatening conditions. Our technology platform is to be used to restore function in the esophagus and the trachea and bronchus airways. Our first generation tracheal implant has been used successfully in five adult human implant procedures approved under compassionate use exemptions, but none of our products are yet approved for marketing by a government regulatory authority. HART is completing further large-animal studies to refine our technology platform with the goals of pursuing one or more compassionate use implantation surgeries and filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in 2016, seeking to initiate clinical trials for one of our three product candidates.
Investor Relations: Catalyst Global LLC David Collins, Tanya Kamatu 212-924-9800 firstname.lastname@example.org
SOURCE Harvard Apparatus Regenerative Technology, Inc.